Nautilus Biotechnology Inc (NAUT)

Currency in USD
0.788
+0.037(+4.93%)
Closed·
After Hours
0.7880.000(0.00%)
·
NAUT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NAUT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.7320.800
52 wk Range
0.6603.090
Key Statistics
Prev. Close
0.751
Open
0.76
Day's Range
0.732-0.8
52 wk Range
0.66-3.09
Volume
350.92K
Average Volume (3m)
313.02K
1-Year Change
-65.59%
Book Value / Share
1.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAUT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.500
Upside
+217.26%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Nautilus Biotechnology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Nautilus Biotechnology Inc Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Inc Earnings Call Summary for Q2/2025

  • Nautilus Biotechnology reported Q2 2025 EPS of -$0.12, beating expectations of -$0.15, a 20% positive surprise
  • Operating expenses decreased 18% YoY to $17.1M, with R&D at $10.4M and G&A at $6.7M; net loss narrowed to $15M from $18M
  • Cash position of $179.5M provides runway through 2027; company maintains strong liquidity with current ratio of 17.36
  • Proteome product launch anticipated in 2026, with potential revenue from proteomics expected in late 2026 or 2027
  • Stock up 1.97% pre-market to $0.76, trading below fair value per InvestingPro analysis despite 71% decline over past year
Last Updated: 31/07/2025, 16:12
Read Full Transcript

Compare NAUT to Peers and Sector

Metrics to compare
NAUT
Peers
Sector
Relationship
P/E Ratio
−1.5x−2.7x−0.5x
PEG Ratio
−0.230.020.00
Price/Book
0.5x1.1x2.6x
Price / LTM Sales
-1.6x3.3x
Upside (Analyst Target)
232.9%119.0%43.5%
Fair Value Upside
Unlock26.0%6.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.500
(+217.26% Upside)

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
-0.12 / -0.15
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NAUT Income Statement

People Also Watch

16.26
SRPT
-2.93%
0.157
VTAK
-1.26%
1.280
CTXR
-5.19%
0.70
ALXO
+6.05%

FAQ

What Stock Exchange Does Nautilus Biotechnology Trade On?

Nautilus Biotechnology is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Nautilus Biotechnology?

The stock symbol for Nautilus Biotechnology is "NAUT."

What Is the Nautilus Biotechnology Market Cap?

As of today, Nautilus Biotechnology market cap is 99.48M.

What Is Nautilus Biotechnology's Earnings Per Share (TTM)?

The Nautilus Biotechnology EPS (TTM) is -0.52.

When Is the Next Nautilus Biotechnology Earnings Date?

Nautilus Biotechnology will release its next earnings report on 03 Nov 2025.

From a Technical Analysis Perspective, Is NAUT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Nautilus Biotechnology Stock Split?

Nautilus Biotechnology has split 0 times.

How Many Employees Does Nautilus Biotechnology Have?

Nautilus Biotechnology has 128 employees.

What is the current trading status of Nautilus Biotechnology (NAUT)?

As of 07 Aug 2025, Nautilus Biotechnology (NAUT) is trading at a price of 0.79, with a previous close of 0.75. The stock has fluctuated within a day range of 0.73 to 0.80, while its 52-week range spans from 0.66 to 3.09.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.